Ambu Weighing Options For CardioPump After Panel Votes Against Approval
This article was originally published in The Gray Sheet
Executive Summary
Ambu is considering its next step in pursuing U.S. marketing of the CardioPump, following a 6-3 vote against approval by FDA's Circulatory System Devices Panel at a June 29 meeting in Rockville, Maryland.